Navigation Links
AMRI Announces Pricing of $130 Million Cash Convertible Senior Notes
Date:11/20/2013

ALBANY, N.Y., Nov. 20, 2013 /PRNewswire/ -- Albany Molecular Research, Inc. (NASDAQ: AMRI) ("AMRI") announced that it has upsized to $130.0 million principal amount and priced its previously announced private offering of cash convertible senior notes due 2018 to qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Securities Act"). AMRI also granted the initial purchasers of the notes an option to purchase up to an additional $20.0 million principal amount of the notes solely to cover over-allotments, if any.

When issued, the notes will be unsecured senior obligations of AMRI and bear interest at a rate of 2.25% per annum, payable semi-annually on May 15 and November 15 of each year, commencing May 15, 2014. The notes will mature on November 15, 2018, unless earlier repurchased or converted into cash in accordance with their terms prior to such date. The notes will be convertible at the option of the holders only in certain circumstances and solely into cash. The notes will not be convertible into AMRI's common stock or any other security under any circumstances. AMRI will not have the right to redeem the notes prior to maturity. The conversion rate for the notes will initially be 63.9844 shares of AMRI's common stock per $1,000 principal amount of notes, which is equivalent to an initial conversion price of approximately $15.63 per share of AMRI's common stock. The initial conversion price of the notes represents a premium of approximately 32.0% to the $11.84 per share last reported sale price of AMRI's common stock on November 19, 2013. The offering of the notes is expected to close on November 25, 2013, subject to customary closing conditions.

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint-bookrunning managers for the offering.

In connection with
'/>"/>

SOURCE AMRI
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Marken Announces Opening of Cold Chain Distribution Hub in Dublin, Ireland
2. Northwest Biotherapeutics Announces Proposed Public Offering Of Common Stock [and Warrants]
3. Tandem Diabetes Care Announces Closing of Initial Public Offering
4. Mylan Announces Pricing of $2.0 Billion of Senior Notes
5. Ultra Clean Announces Participation in the 2nd Annual Midtown CAP Summit Investor Conference
6. Simcere Pharmaceutical Group Announces Extraordinary General Meeting of Shareholders
7. Assurex Health Announces International Expansion through Canadian Partnership with the Centre for Addiction and Mental Health
8. PBL Assay Science announces ultra-sensitive assay services to measure biomolecules in human serum or plasma
9. Irvine Center for Clinical Research Announces Open Enrollment for New Low Testosterone Study
10. American Medical Systems Announces 500th Patient Enrolled in PROPPER Registry
11. OncoGenex Announces Update on Phase 3 SYNERGY Trial Evaluating Custirsen in Men with Metastatic Castrate-Resistant Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... SAN FRANCISCO , Aug. 3, 2015  Sage ... generation of portable laboratory-quality cannabis potency measurement systems, announced ... PAC Bay Area Cruise Fundraiser. A limited number of ... the festivities and help a great cause while enjoying ... a scenic cruise around the San Francisco Bay at ...
(Date:8/3/2015)... -- Depomed, Inc. (NASDAQ: DEPO ) ("Depomed" or the ... HZNP ) ("Horizon") announcement that it intends to request ... record date to determine the shareholders eligible to request ... will review the request when it is received. Provided ... information required under Depomed,s bylaws, the Depomed Board will, ...
(Date:8/3/2015)... NEW YORK , August 3, 2015 /PRNewswire/ ... report published by Persistence Market Research "Global Market ... to Witness Highest Growth by 2022", ... at US$15 Bn by the end of 2015 and ... 6.8% from 2015 to 2022, to account for ...
Breaking Medicine Technology:Sage Analytics Sponsors California Cannabis Industry Association Bay Area Cruise FUNdraiser 2Depomed Comments on Horizon Pharma Announcement 2Depomed Comments on Horizon Pharma Announcement 3Depomed Comments on Horizon Pharma Announcement 4Depomed Comments on Horizon Pharma Announcement 5Depomed Comments on Horizon Pharma Announcement 6Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 2Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 3Global Physiotherapy Equipment Market Will Reach US$ 23.7 Billion by 2022: Persistence Market Research 4
... PRO-DEX, INC. (Nasdaq: PDEX ) invites investors and ... fiscal 2012 first quarter financial results. (Logo:   ... be broadcast live over the internet on Wednesday, November 9, ... and may be accessed by visiting the Company,s website at ...
... VIEW, Calif., Nov. 3, 2011 VIVUS, Inc. (NASDAQ: ... were published in Obesity, the peer-reviewed journal of The ... the investigational drug Qnexa in 1,267 severely obese (BMI >/= 35 ... addition to average weight loss of 14.4% of initial body weight ...
Cached Medicine Technology:Pro-Dex, Inc. Announces Fiscal 2012 First Quarter Financial Results Conference Call and Webcast 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 2Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 3Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 4Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 5Qnexa® Phase 3 Data Published In Obesity Show 14.4% Average Weight Loss In Severely Obese Patients Completing One Year Of Treatment 6
(Date:8/3/2015)... Angeles, CA (PRWEB) , ... August 03, 2015 , ... ... Back Pain: Injection of Stem Cells Found to Release Natural Painkiller That Can Last ... pain in patients. According to the report, the new study showed that harvesting stem ...
(Date:8/3/2015)... ... August 03, 2015 , ... Illinois Health & Science (IHS) has completed ... The acquisition includes all of IBAM NA’s cyclotron sites and research and development facilities. ... regionally located business, as well as a large manufacturing hub in Noblesville, Indiana,” said ...
(Date:8/3/2015)... (PRWEB) , ... August 03, 2015 , ... ... insurance brokerage firm, announced today that Joe Williams has joined its growing California ... and delivering HUB's differentiated service model to his clients. Mr. Williams will be ...
(Date:8/3/2015)... ... 03, 2015 , ... Cambia Health Solutions has promoted Scott ... company’s Medicare and Federal Employee Programs (FEP) lines of business. , Government ... members. In this role, Scott is responsible for overseeing the growth, finance and ...
(Date:8/3/2015)... ... August 03, 2015 , ... Examination ... and investigative services, has introduced a new logo and comprehensive brand strategy ... improve business outcomes for its customers. EMSI’s new tagline, “Powerful Information. Improved ...
Breaking Medicine News(10 mins):Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 2Health News:Los Angeles Spine Surgeon Gives Insight into How Stem Cells Can Relieve Back Pain 3Health News:Illinois Health & Science Expands Nuclear Medicine Footprint With Purchase of IBA Molecular North America, Inc. 2Health News:HUB International Insurance Services Announces Joe Williams Has Joined its Northern California Employee Benefits Division 2Health News:Cambia Health Solutions Names Scott Powers President of Government Programs 2Health News:EMSI Announces New Branding: Powerful Information. Improved Outcomes. 2
... Mich., Dec. 10 GeneGo, Inc., a leading,provider of ... analysis ,today announced that A*STAR,s Singapore Immunology Network (SIgN) ... researchers will have access,to GeneGo,s MetaCore, training and advanced ... for all SIgN researchers. , ...
... in one resource the necessary information to make an informed decision when ... ... Lyndhurst, NJ (PRWEB) December 10, 2008 -- From picking a great pediatrician ... is), navigating the medical landscape can be a daunting task, especially if ...
... www.patheon.com , , ... Patheon (TSX:PTI), a global provider of drug development and ... to announce the opening of its new U.S. headquarters ... Triangle Park (RTP), North Carolina. , Established ...
... Trials and the Company,s Other Clinical Programs All Advanced During the ... Validation Achieved for Bavituximab and Peregrine,s Anti-PS Anti-Viral Platform in Nature ... Company Enters into Loan Agreement for Up to $10 Million in ... Dec. 10 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) ...
... , , TUCSON, Ariz., Dec. ... PRSC ) today announced that its Board of Directors has ... shareholders will receive rights to purchase shares of the Company,s ... , "In this period of unprecedented market volatility ...
... Consumers Advised to Secure Long Term Care Insurance While They,re ... KIRKLAND, Wash., Dec. 10 If you,ve put ... off a bit longer, anticipating the new administration,s health plan? ... Board of LTC Financial Partners LLC (LTCFP), one of the ...
Cached Medicine News:Health News:A*STAR's Singapore Immunology Network Is the First GeneGo Center of Excellence in Asia 2Health News:Vitals Launches Free eBook to Help Consumers Find "Dr. Right" 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 2Health News:Patheon Opens New U.S. Headquarters and Analytical Laboratory Facility in Research Triangle Park, NC 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 2Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 3Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 4Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 5Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 6Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 7Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 8Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 9Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 10Health News:Peregrine Pharmaceuticals Reports Financial Results for the Second Quarter of Fiscal Year 2009 11Health News:Providence Service Corporation Adopts Shareholder Rights Plan 2Health News:Providence Service Corporation Adopts Shareholder Rights Plan 3Health News:Obama Health Plan Not Likely to Embrace Long Term Care, Industry Leader Says 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: